IL291174B2 - Process for the preparation of a medicament containing an oxepane ring. - Google Patents
Process for the preparation of a medicament containing an oxepane ring.Info
- Publication number
- IL291174B2 IL291174B2 IL291174A IL29117422A IL291174B2 IL 291174 B2 IL291174 B2 IL 291174B2 IL 291174 A IL291174 A IL 291174A IL 29117422 A IL29117422 A IL 29117422A IL 291174 B2 IL291174 B2 IL 291174B2
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- medicament containing
- oxepane ring
- oxepane
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898861P | 2019-09-11 | 2019-09-11 | |
| US201962934382P | 2019-11-12 | 2019-11-12 | |
| PCT/US2020/050086 WO2021050654A1 (en) | 2019-09-11 | 2020-09-10 | Process for the preparation of a medicament containing an oxepane ring. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL291174A IL291174A (en) | 2022-05-01 |
| IL291174B1 IL291174B1 (en) | 2024-12-01 |
| IL291174B2 true IL291174B2 (en) | 2025-04-01 |
Family
ID=72614037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291174A IL291174B2 (en) | 2019-09-11 | 2020-09-10 | Process for the preparation of a medicament containing an oxepane ring. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11414412B2 (en) |
| EP (1) | EP4028396B1 (en) |
| JP (1) | JP7370457B2 (en) |
| KR (1) | KR102786186B1 (en) |
| CN (1) | CN114341134B (en) |
| AU (1) | AU2020345916B2 (en) |
| BR (1) | BR112022004455B1 (en) |
| CA (1) | CA3147844A1 (en) |
| CL (1) | CL2022000581A1 (en) |
| CR (1) | CR20220100A (en) |
| ES (1) | ES2972049T3 (en) |
| IL (1) | IL291174B2 (en) |
| MX (1) | MX2022002962A (en) |
| MY (1) | MY208408A (en) |
| PE (1) | PE20220709A1 (en) |
| PL (1) | PL4028396T3 (en) |
| SA (1) | SA522431923B1 (en) |
| TW (1) | TWI856177B (en) |
| WO (1) | WO2021050654A1 (en) |
| ZA (1) | ZA202202178B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130296569A1 (en) * | 2010-11-03 | 2013-11-07 | Vijaykumar Jagdishwar Patil | Process for the preparation of phosphoric acid mono-(1--4-methoxymethyl-piperidin-4-yl) ester |
| WO2014048939A1 (en) | 2012-09-26 | 2014-04-03 | F. Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| MX2016012007A (en) * | 2014-03-18 | 2016-12-05 | Hoffmann La Roche | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. |
| SE540295C2 (en) * | 2016-12-05 | 2018-05-29 | Glactone Pharma Dev Ab | Sulfonamide analogues of galiellalactone |
-
2020
- 2020-09-09 TW TW109130966A patent/TWI856177B/en active
- 2020-09-10 MX MX2022002962A patent/MX2022002962A/en unknown
- 2020-09-10 US US17/016,900 patent/US11414412B2/en active Active
- 2020-09-10 KR KR1020227008173A patent/KR102786186B1/en active Active
- 2020-09-10 AU AU2020345916A patent/AU2020345916B2/en active Active
- 2020-09-10 CA CA3147844A patent/CA3147844A1/en active Pending
- 2020-09-10 CN CN202080062691.1A patent/CN114341134B/en active Active
- 2020-09-10 MY MYPI2022001035A patent/MY208408A/en unknown
- 2020-09-10 IL IL291174A patent/IL291174B2/en unknown
- 2020-09-10 ES ES20776038T patent/ES2972049T3/en active Active
- 2020-09-10 CR CR20220100A patent/CR20220100A/en unknown
- 2020-09-10 PE PE2022000381A patent/PE20220709A1/en unknown
- 2020-09-10 JP JP2022515639A patent/JP7370457B2/en active Active
- 2020-09-10 BR BR112022004455-0A patent/BR112022004455B1/en active IP Right Grant
- 2020-09-10 PL PL20776038.0T patent/PL4028396T3/en unknown
- 2020-09-10 WO PCT/US2020/050086 patent/WO2021050654A1/en not_active Ceased
- 2020-09-10 EP EP20776038.0A patent/EP4028396B1/en active Active
-
2022
- 2022-02-21 ZA ZA2022/02178A patent/ZA202202178B/en unknown
- 2022-03-09 CL CL2022000581A patent/CL2022000581A1/en unknown
- 2022-03-10 SA SA522431923A patent/SA522431923B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI856177B (en) | 2024-09-21 |
| SA522431923B1 (en) | 2024-04-15 |
| CN114341134B (en) | 2024-03-08 |
| ES2972049T3 (en) | 2024-06-10 |
| EP4028396A1 (en) | 2022-07-20 |
| CN114341134A (en) | 2022-04-12 |
| JP7370457B2 (en) | 2023-10-27 |
| EP4028396B1 (en) | 2024-01-03 |
| AU2020345916B2 (en) | 2026-08-13 |
| US11414412B2 (en) | 2022-08-16 |
| PL4028396T3 (en) | 2024-04-29 |
| JP2022547536A (en) | 2022-11-14 |
| TW202116309A (en) | 2021-05-01 |
| CL2022000581A1 (en) | 2022-10-07 |
| CR20220100A (en) | 2022-05-23 |
| US20210070749A1 (en) | 2021-03-11 |
| BR112022004455B1 (en) | 2024-04-30 |
| BR112022004455A2 (en) | 2022-06-14 |
| KR102786186B1 (en) | 2025-03-27 |
| IL291174A (en) | 2022-05-01 |
| EP4028396C0 (en) | 2024-01-03 |
| CA3147844A1 (en) | 2021-03-18 |
| MX2022002962A (en) | 2022-09-29 |
| PE20220709A1 (en) | 2022-05-04 |
| WO2021050654A1 (en) | 2021-03-18 |
| IL291174B1 (en) | 2024-12-01 |
| MY208408A (en) | 2025-05-08 |
| AU2020345916A1 (en) | 2022-03-03 |
| ZA202202178B (en) | 2024-06-26 |
| KR20220047324A (en) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102696B (en) | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof | |
| GB201903767D0 (en) | Multimers, tetramers & octamers | |
| EP4349406A3 (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament | |
| WO2016079751A3 (en) | A process for preparation of vortioxetine and polymorphs thereof | |
| PL3736228T3 (en) | Capsule for preparing a beverage, method of producing the same and use of the capsule | |
| CA190818S (en) | Ring | |
| PH12020500105A1 (en) | Bicyclic ketone compounds and methods of use thereof | |
| GB2593352B (en) | Process for the preparation of 3alpha-hydroxy-5alpha-pregnan-20-one (brexanolone) | |
| IL289904B1 (en) | Process for the preparation of biphenylamines | |
| ZA202006907B (en) | A fatty preparation, a process for making said fatty preparation, and a product containing the same | |
| WO2016055647A3 (en) | Method for preparing universal plasma | |
| IL283633A (en) | Process for the preparation of a cyclic dinucleotide | |
| IL286743A (en) | Capsule for infusion products | |
| PL4037679T3 (en) | A process for the preparation of highly pure valsartan | |
| IL291174A (en) | Process for the preparation of a medicament containing an oxepane ring. | |
| IL286054A (en) | Process for the preparation of a substituted imidazoquinoline | |
| ZA202102159B (en) | Process for the preparation of a flavouring | |
| PL3774752T3 (en) | Process for the preparation of glycidol | |
| PL3725774T3 (en) | Process for the preparation of a pharmaceutical agent | |
| EP3902982A4 (en) | A nozzle ring structure | |
| EP3273967A4 (en) | A process for the preparation of lorcaserin hydrochloride | |
| ZA202006906B (en) | A fatty preparation, a process for making said fatty preparation, and a product containing the same | |
| IL288972A (en) | Continuous process for the preparation of anticholinergic drugs | |
| HK40063705A (en) | Medicament container | |
| EP4013502B8 (en) | Process for the preparation of a pyrimidino-diazepine derivative |